Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Black Diamond Therapeutics, Inc.BDTX · Entity 6669 | Director · PRESIDENT & CEO | January 21, 2026 | January 23, 2026 |
| G1 Therapeutics, Inc.GTHX · Entity 87413 | Director | August 08, 2023 | August 10, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Black Diamond Therapeutics, Inc.
Report date January 21, 2026 · Filed January 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.57 · Expires 2036-01-20 | Direct | 600,000 |
Reported balance
After 2026-01-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-21 · Grant · Acquired 600,000 · Balance 600,000 F1: 25% of the shares subject to this option shall vest and become exercisable on January 21, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to this option shall vest and become exercisable on January 21, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
G1 Therapeutics, Inc.
Report date August 08, 2023 · Filed August 10, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 116,000 |
Ending reported balance
After 2023-08-08 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2023-08-08 · Exercise / conversion · Acquired 57,286 · Balance 173,286 Row 2 · 2023-08-08 · Sale · Disposed 57,286 · Balance 116,000 F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F2: The price represents the weighted average price with a low of $1.98 and a high of $2.06. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth. Row 3 · 2023-08-08 · Exercise / conversion · Acquired 2,714 · Balance 118,714 Row 4 · 2023-08-08 · Sale · Disposed 2,714 · Balance 116,000 F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.39 · Expires 2024-05-09 | Direct | 0 |
Reported balance
After 2023-08-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-08-08 · Exercise / conversion · Disposed 57,286 · Balance 0 F3: All shares underlying this option have vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.30 · Expires 2025-02-27 | Direct | 242,286 |
Reported balance
After 2023-08-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-08-08 · Exercise / conversion · Disposed 2,714 · Balance 242,286 F3: All shares underlying this option have vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
F2: The price represents the weighted average price with a low of $1.98 and a high of $2.06. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth.
F3: All shares underlying this option have vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2021 Filed Jun 17, 2021 16:05 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | SaleCommon Stock | 10,000 | $22.39 | $223,909.00 |
DisclosureSEC source: 0001562180-21-004348 · primarydocument.xml · nonDerivative · entry 2 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,000 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price represents the weighted average price with a low of $22.10 and a high of $22.64. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 16:05 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionCommon Stock | 10,000 | $0.39 | $3,900.00 |
DisclosureSEC source: 0001562180-21-004348 · primarydocument.xml · nonDerivative · entry 1 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 25, 2021 Filed May 25, 2021 18:29 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionStock Options (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001562180-21-003737 · primarydocument.xml · derivative · entry 2 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,286 Underlying: Common Stock · 20,000 shares Expires 2024-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| May 25, 2021 Filed May 25, 2021 18:29 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionCommon Stock | 20,000 | $0.39 | $7,800.00 |
DisclosureSEC source: 0001562180-21-003737 · primarydocument.xml · nonDerivative · entry 1 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 13, 2021 Filed May 13, 2021 16:43 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionStock Options (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001562180-21-003460 · primarydocument.xml · derivative · entry 9 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,286 Underlying: Common Stock · 10,000 shares Expires 2024-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| May 13, 2021 Filed May 13, 2021 16:43 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | SaleCommon Stock | 10,000 | $20.54 | $205,413.00 |
DisclosureSEC source: 0001562180-21-003460 · primarydocument.xml · nonDerivative · entry 6 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,000 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price represents the weighted average price with a low of $20.42 and a high of $20.895. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 4 to this Form 4. Read SEC document |
| May 13, 2021 Filed May 13, 2021 16:43 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionCommon Stock | 10,000 | $0.39 | $3,900.00 |
DisclosureSEC source: 0001562180-21-003460 · primarydocument.xml · nonDerivative · entry 5 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2021 Filed May 13, 2021 16:43 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionStock Options (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001562180-21-003460 · primarydocument.xml · derivative · entry 8 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,286 Underlying: Common Stock · 10,000 shares Expires 2024-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| May 12, 2021 Filed May 13, 2021 16:43 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | SaleCommon Stock | 10,000 | $20.07 | $200,691.00 |
DisclosureSEC source: 0001562180-21-003460 · primarydocument.xml · nonDerivative · entry 4 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,000 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price represents the weighted average price with a low of $19.80 and a high of $20.28. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 3 to this Form 4. Read SEC document |
| May 12, 2021 Filed May 13, 2021 16:43 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionCommon Stock | 10,000 | $0.39 | $3,900.00 |
DisclosureSEC source: 0001562180-21-003460 · primarydocument.xml · nonDerivative · entry 3 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2021 Filed May 13, 2021 16:43 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionStock Options (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001562180-21-003460 · primarydocument.xml · derivative · entry 7 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,286 Underlying: Common Stock · 10,000 shares Expires 2024-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| May 11, 2021 Filed May 13, 2021 16:43 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | SaleCommon Stock | 10,000 | $19.10 | $190,997.00 |
DisclosureSEC source: 0001562180-21-003460 · primarydocument.xml · nonDerivative · entry 2 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,000 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price represents the weighted average price with a low of $18.69 and a high of $19.47. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4. Read SEC document |
| May 11, 2021 Filed May 13, 2021 16:43 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionCommon Stock | 10,000 | $0.39 | $3,900.00 |
DisclosureSEC source: 0001562180-21-003460 · primarydocument.xml · nonDerivative · entry 1 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 15, 2021 Filed Apr 15, 2021 17:53 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionStock Options (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001562180-21-002835 · primarydocument.xml · derivative · entry 9 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,286 Underlying: Common Stock · 10,000 shares Expires 2024-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| April 15, 2021 Filed Apr 15, 2021 17:53 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | SaleCommon Stock | 10,000 | $24.96 | $249,631.00 |
DisclosureSEC source: 0001562180-21-002835 · primarydocument.xml · nonDerivative · entry 6 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,000 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price represents the weighted average price with a low of $24.62 and a high of $25.33. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 4 to this Form 4. Read SEC document |
| April 15, 2021 Filed Apr 15, 2021 17:53 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionCommon Stock | 10,000 | $0.39 | $3,900.00 |
DisclosureSEC source: 0001562180-21-002835 · primarydocument.xml · nonDerivative · entry 5 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 14, 2021 Filed Apr 15, 2021 17:53 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionStock Options (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001562180-21-002835 · primarydocument.xml · derivative · entry 8 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347,286 Underlying: Common Stock · 10,000 shares Expires 2024-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| April 14, 2021 Filed Apr 15, 2021 17:53 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | SaleCommon Stock | 10,000 | $24.53 | $245,272.00 |
DisclosureSEC source: 0001562180-21-002835 · primarydocument.xml · nonDerivative · entry 4 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,000 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price represents the weighted average price with a low of $24.24 and a high of $24.81. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 3 to this Form 4. Read SEC document |
| April 14, 2021 Filed Apr 15, 2021 17:53 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionCommon Stock | 10,000 | $0.39 | $3,900.00 |
DisclosureSEC source: 0001562180-21-002835 · primarydocument.xml · nonDerivative · entry 3 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 17:53 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionStock Options (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001562180-21-002835 · primarydocument.xml · derivative · entry 7 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 357,286 Underlying: Common Stock · 10,000 shares Expires 2024-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 17:53 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | SaleCommon Stock | 10,000 | $23.89 | $238,865.00 |
DisclosureSEC source: 0001562180-21-002835 · primarydocument.xml · nonDerivative · entry 2 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,000 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price represents the weighted average price with a low of $23.68 and a high of $24.05. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 17:53 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionCommon Stock | 10,000 | $0.39 | $3,900.00 |
DisclosureSEC source: 0001562180-21-002835 · primarydocument.xml · nonDerivative · entry 1 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2021 Filed Feb 18, 2021 17:49 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionStock Options (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $3.72 | $0.00 |
DisclosureSEC source: 0001562180-21-001280 · primarydocument.xml · derivative · entry 12 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,393 Underlying: Common Stock · 10,000 shares Expires 2025-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| February 18, 2021 Filed Feb 18, 2021 17:49 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | SaleCommon Stock | 10,000 | $26.02 | $260,152.00 |
DisclosureSEC source: 0001562180-21-001280 · primarydocument.xml · nonDerivative · entry 9 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,000 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The price represents the weighted average price with a low of $25.88 and a high of $26.31. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 6 to this Form 4. Read SEC document |
| February 18, 2021 Filed Feb 18, 2021 17:49 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionCommon Stock | 10,000 | $3.72 | $37,200.00 |
DisclosureSEC source: 0001562180-21-001280 · primarydocument.xml · nonDerivative · entry 8 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 17:49 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionStock Options (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $3.72 | $0.00 |
DisclosureSEC source: 0001562180-21-001280 · primarydocument.xml · derivative · entry 11 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,393 Underlying: Common Stock · 10,000 shares Expires 2025-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 17:49 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | SaleCommon Stock | 600 | $28.41 | $17,046.00 |
DisclosureSEC source: 0001562180-21-001280 · primarydocument.xml · nonDerivative · entry 7 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,000 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price represents the weighted average price with a low of $28.40 and a high of $28.42. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 5 to this Form 4. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 17:49 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | SaleCommon Stock | 9,400 | $27.59 | $259,387.36 |
DisclosureSEC source: 0001562180-21-001280 · primarydocument.xml · nonDerivative · entry 6 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,600 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price represents the weighted average price with a low of $27.25 and a high of $28.21. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 4 to this Form 4. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 17:49 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionCommon Stock | 10,000 | $3.72 | $37,200.00 |
DisclosureSEC source: 0001562180-21-001280 · primarydocument.xml · nonDerivative · entry 5 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 17:49 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionStock Options (Right to Buy) · Derivative | 11,040 | $0.00 Strike: $3.72 | $0.00 |
DisclosureSEC source: 0001562180-21-001280 · primarydocument.xml · derivative · entry 10 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,393 Underlying: Common Stock · 11,040 shares Expires 2025-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 17:49 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | SaleCommon Stock | 23 | $37.00 | $851.00 |
DisclosureSEC source: 0001562180-21-001280 · primarydocument.xml · nonDerivative · entry 4 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,000 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 17:49 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | SaleCommon Stock | 2,700 | $36.22 | $97,780.50 |
DisclosureSEC source: 0001562180-21-001280 · primarydocument.xml · nonDerivative · entry 3 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,023 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price represents the weighted average price with a low of $35.84 and a high of $36.785. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 3 to this Form 4. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 17:49 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | SaleCommon Stock | 8,317 | $34.87 | $290,021.28 |
DisclosureSEC source: 0001562180-21-001280 · primarydocument.xml · nonDerivative · entry 2 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,723 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price represents the weighted average price with a low of $34.71 and a high of $35.36. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 17:49 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionCommon Stock | 11,040 | $3.72 | $41,068.80 |
DisclosureSEC source: 0001562180-21-001280 · primarydocument.xml · nonDerivative · entry 1 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,040 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 21, 2021 Filed Jan 21, 2021 17:31 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionStock Options (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $3.72 | $0.00 |
DisclosureSEC source: 0001562180-21-000442 · primarydocument.xml · derivative · entry 11 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,433 Underlying: Common Stock · 10,000 shares Expires 2025-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| January 21, 2021 Filed Jan 21, 2021 17:31 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | SaleCommon Stock | 10,000 | $20.64 | $206,400.00 |
DisclosureSEC source: 0001562180-21-000442 · primarydocument.xml · nonDerivative · entry 7 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,000 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price represents the weighted average price with a low of $20.34 and a high of $20.94. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 4 to this Form 4. Read SEC document |
| January 21, 2021 Filed Jan 21, 2021 17:31 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionCommon Stock | 10,000 | $3.72 | $37,200.00 |
DisclosureSEC source: 0001562180-21-000442 · primarydocument.xml · nonDerivative · entry 6 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 20, 2021 Filed Jan 21, 2021 17:31 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionStock Options (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001562180-21-000442 · primarydocument.xml · derivative · entry 10 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,286 Underlying: Common Stock · 4,000 shares Expires 2024-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| January 20, 2021 Filed Jan 21, 2021 17:31 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionStock Options (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $3.72 | $0.00 |
DisclosureSEC source: 0001562180-21-000442 · primarydocument.xml · derivative · entry 9 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,433 Underlying: Common Stock · 10,000 shares Expires 2025-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| January 20, 2021 Filed Jan 21, 2021 17:31 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionCommon Stock | 4,000 | $0.39 | $1,560.00 |
DisclosureSEC source: 0001562180-21-000442 · primarydocument.xml · nonDerivative · entry 5 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 20, 2021 Filed Jan 21, 2021 17:31 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | SaleCommon Stock | 10,000 | $21.51 | $215,107.00 |
DisclosureSEC source: 0001562180-21-000442 · primarydocument.xml · nonDerivative · entry 4 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,000 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price represents the weighted average price with a low of $21.30 and a high of $21.74. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 3 to this Form 4. Read SEC document |
| January 20, 2021 Filed Jan 21, 2021 17:31 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionCommon Stock | 10,000 | $3.72 | $37,200.00 |
DisclosureSEC source: 0001562180-21-000442 · primarydocument.xml · nonDerivative · entry 3 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 17:31 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionStock Options (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $3.72 | $0.00 |
DisclosureSEC source: 0001562180-21-000442 · primarydocument.xml · derivative · entry 8 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,433 Underlying: Common Stock · 10,000 shares Expires 2025-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 17:31 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | SaleCommon Stock | 10,000 | $20.88 | $208,781.00 |
DisclosureSEC source: 0001562180-21-000442 · primarydocument.xml · nonDerivative · entry 2 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,000 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price represents the weighted average price with a low of $20.64 and a high of $21.35. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 17:31 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionCommon Stock | 10,000 | $3.72 | $37,200.00 |
DisclosureSEC source: 0001562180-21-000442 · primarydocument.xml · nonDerivative · entry 1 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 17, 2020 Filed Dec 17, 2020 18:01 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionStock Options (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $3.72 | $0.00 |
DisclosureSEC source: 0001562180-20-007341 · primarydocument.xml · derivative · entry 9 Velleca Mark A. · CIK 0001706847 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,433 Underlying: Common Stock · 10,000 shares Expires 2025-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| December 17, 2020 Filed Dec 17, 2020 18:01 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | SaleCommon Stock | 10,000 | $19.97 | $199,668.00 |
DisclosureSEC source: 0001562180-20-007341 · primarydocument.xml · nonDerivative · entry 6 Velleca Mark A. · CIK 0001706847 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,000 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price represents the weighted average price with a low of $19.75 and a high of $20.22. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 4 to this Form 4. Read SEC document |
| December 17, 2020 Filed Dec 17, 2020 18:01 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionCommon Stock | 10,000 | $3.72 | $37,200.00 |
DisclosureSEC source: 0001562180-20-007341 · primarydocument.xml · nonDerivative · entry 5 Velleca Mark A. · CIK 0001706847 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 18:01 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionStock Options (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $3.72 | $0.00 |
DisclosureSEC source: 0001562180-20-007341 · primarydocument.xml · derivative · entry 8 Velleca Mark A. · CIK 0001706847 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,433 Underlying: Common Stock · 10,000 shares Expires 2025-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 18:01 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | SaleCommon Stock | 10,000 | $19.20 | $192,021.00 |
DisclosureSEC source: 0001562180-20-007341 · primarydocument.xml · nonDerivative · entry 4 Velleca Mark A. · CIK 0001706847 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,000 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price represents the weighted average price with a low of $19.04 and a high of $19.37. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 3 to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.